Company: ACBM
Filing Date: 2025-07-18
Form Type: 10-K
Source: 0001640334-25-001245
Chunk: 520

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-18
Form: 10-K
Item: Item 8
Chunk 520
---
 which was $2.85 and $2.20 per share, respectively, and was amortized over two-year period starting from the date of the agreement using the straight-line method. During the year ended December 31, 2023 and 2022, the Company recorded stock-based compensation of $8,060,983 and $15,712,400, respectively, and had deferred stock compensation of $0 and $8,060,983 as of December 31, 2023 and 2022, respectively. At December 31, 2023, these stock grants were fully amortized. During the years ended December 31, 2023 and 2022, the Company did not issue any shares of common stock.

 F-12Table of Contents

NOTE 5 - INCOME TAXES The reconciliation of income tax expense at the U.S. statutory rate of 21% to the Company’s effective tax rate is as follows:   Year Ended   December 31,   2023  2022 Income tax expense (benefit) at statutory rate $(1,849,590) $(3,333,003)Income tax adjustment        Imputed interest  673   358 Change of valuation allowance  1,848,917   3,332,645 Income tax expense (benefit) $-  $-  Net deferred tax assets consist of the following components as of:    December 31,  December 31,   2023  2022 Operating loss carry forward                                          $6,863,858  $5,014,941 Valuation allowance  (6,863,858)  (5,014,941)Deferred tax asset $-  $- The Company has approximately $33 million net operating loss carryforwards that are available to reduce future taxable income. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax assets for the year ended December 31,